Vanguard Asset Management
IMNM icon

Vanguard Asset Management’s Immunome IMNM Stock Holding History

Vanguard Asset Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
66,730
+7,330
+12% +$157K ﹤0.01% 1723
2026
Q1 		$1.3M Buy
+59,400
New +$1.32M ﹤0.01% 1667

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vanguard Asset Management's IMNM Position: Q2 2026 in Review

Vanguard Asset Management increased its Immunome (IMNM) stake by 12% in Q2 2026, buying an estimated $157K and bringing the position to 66,730 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1723.

Vanguard Asset Management first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Vanguard Asset Management held 66,730 shares of Immunome worth $1.41M as of Q2 2026.
  • Vanguard Asset Management bought 7,330 Immunome shares in Q2 2026, an estimated $157K.
  • Immunome made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1723 holding.
  • Vanguard Asset Management first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.